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Background: We have studied the effect of 
caveolin-1 deficiency on the mechanisms that 
regulate free arachidonic acid availability.  
Results: Macrophages from caveolin-1-
deficient mice exhibit elevated fatty acid 
incorporation and remodeling and a 
constitutively increased CoA-independent 
transacylase activity.  
Conclusion: Macrophages from caveolin-1 
null mice show decreased arachidonate 
mobilization and eicosanoid production upon 
cell stimulation.  
Significance: Caveolin-1 may play an 
important and previously unrecognized role in 
the eicosanoid biosynthetic response of 
macrophages. 
 
In this work we have studied the effect of 
caveolin-1 deficiency on the mechanisms 
that regulate free arachidonic acid (AA) 
availability. Results presented here 
demonstrate that macrophages from 
caveolin-1-deficient mice exhibit elevated 
fatty acid incorporation and remodeling and 
a constitutively increased CoA-independent 
transacylase activity. Mass spectrometry-
based lipidomic analyses reveal stable 
alterations in the profile of AA distribution 
among phospholipids, manifested by 
reduced levels of AA in choline 
glycerophospholipids but elevated levels in 
ethanolamine glycerophospholipids and 
phosphatidylinositol. Furthermore, 
macrophages from caveolin-1 null mice 
show decreased AA mobilization and PGE2 
and LTB4 production upon cell stimulation. 
Collectively, these results provide insight 
into the role of caveolin-1 in AA homeostasis 
and suggest an important role for this 
protein in the eicosanoid biosynthetic 
response. 
 
The potent biological activity of the 
eicosanoids, lipid mediators that play key roles 
in inflammation [1], compels the cells to 
tightly control the free levels of their common 
precursor, 5,8,11,14-eicosatetraenoic acid or 
arachidonic acid (AA1, 20:4n-6). AA is an 
intermediate of a deacylation/reacylation cycle 
of membrane phospholipids, the so-called 
Lands cycle, in which the fatty acid is cleaved 
from the sn-2 position of glycerophospholipids 
by the action of phospholipases A2 and 
reacylated back to phospholipids by the 
combined action of acyl-CoA synthetases and 
CoA-dependent acyltransferases [2,3]. In 
resting unstimulated cells, the reacylation 
reactions dominate over the phospholipase A2-
mediated deacylation step; thus free AA is kept 
at very low levels. Stimulation of the cells by 
receptor agonists results in the activation of 
intracellular phospholipases A2 [4-8]. Under 
these conditions, the rate of AA release clearly 
exceeds that of reincorporation into 
phospholipids; hence, net accumulation of free 
AA occurs that is followed by its conversion 
into various eicosanoids. 
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AA bound to phospholipid is also the 
subject of successive transacylation reactions 
aimed at ensuring the proper distribution of the 
fatty acid within the various cellular 
phospholipid pools [2]. This appears to be 
important not only for membrane homeostasis 
but also for the execution of appropriate cell 
responses during physiological and 
pathophysiological activation [9-12]. These 
transacylation reactions are catalyzed by CoA-
independent transacylase (CoA-IT), an enzyme 
that transfers AA moieties preferentially from 
diacyl PC species to PE plasmalogens [2]. 
Caveolin-1 is the main protein in the 
caveolae, membrane domains enriched in 
cholesterol and sphingolipids that play 
structural and signaling roles [13-15]. 
Caveolin-1 is abundant in adipocytes, 
endothelial cells, and smooth muscle cells 
[14]. Until recently, the presence of caveolae 
and caveolin-1 in immune cells was a 
controversial issue [16, 17], and probably as a 
consequence of this, little information exists on 
its involvement in macrophage immune 
responses. Recently however, caveolae have 
been shown to be involved in the 
internalization of pathogens [18]. 
The generation of caveolin-1 null mice 
[19, 20] has permitted a better understanding 
of the specific functions of this protein as well 
as its physiological relevance. Caveolin-1-
deficient mice are viable and fertile and exhibit 
resistance to diet-induced obesity, a tendency 
to be leaner, and alterations in the plasma 
profile of lipids and lipoproteins [21, 22]. 
Given that caveolin-1 displays fatty 
acid binding properties [23], in this work we 
have studied the possible participation of this 
protein on the mechanisms that control 
arachidonate (AA) availability in 
immunoinflammatory cells. Our data suggest 
that lack of caveolin-1 promotes marked 
changes in the distribution of AA among 
cellular phospholipids, with direct 
consequences on the eicosanoid biosynthetic 
response induced by innate immune stimuli 
 
 
MATERIALS AND METHODS 
 
Reagents - RPMI 1640 medium was from 
Invitrogen Life Technologies (San Diego, CA). 
[5,6,8,9,11,12,14,15-3H]AA (specific activity 
211 Ci/mmol) and radioactive substrates for 
enzyme assays were from GE Healthcare 
(Alcobendas, Madrid, Spain). Thin-layer 
chromatography plates were from Scharlab 
(Barcelona, Spain). All other reagents were 
from Sigma. 
 
Animals – Caveolin-1-deficient mice, strain 
Cav-1 tm1Mls/J, and their wild type controls, 
strain B6129SF2/J [20], were obtained from 
The Jackson Laboratory (Bar Harbor, ME). For 
some experiments, the caveolin-1-deficient 
mice produced by Drab et al. [19] were also 
used. Mice were maintained according to the 
animal care standards established by the 
European Union. 
 
Cell culture - Resident peritoneal macrophages 
were obtained by peritoneal lavage using 5 ml 
of cold PBS as described [24]. The cells were 
plated at 2 x 106 per well (6-well plates) in 2 
ml of RPMI with 10% heat inactivated serum, 
and allowed to adhere for 20 h in a humidified 
atmosphere of 5% CO2 at 37oC. Wells were 
then extensively washed with PBS to remove 
non-adherent cells. Adherent macrophages 
were then used for experimentation.  
 
Measurement of [3H]AA incorporation into 
cellular lipids - Macrophages were either 
untreated or treated with exogenous [3H]AA 
(0.25 μCi/ml) at the indicated concentrations. 
At different times, the reactions were stopped 
by replacing the incubation medium with ice-
cold 0.1% Triton X-100, and total lipids were 
then extracted according to the method of 
Bligh and Dyer [25] and separated by thin-
layer chromatography. Phospholipids and 
neutral lipids were separated with 
hexane/ether/acetic acid (70:30:1, v/v/v) as a 
mobile phase. The spots were cut out and 
analyzed for radioactivity by liquid 
scintillation counting [26]. For analysis of the 
molecular species into which the exogenous 
fatty acid was incorporated, [2H]AA was used 
instead of [3H]AA and the various [2H]AA-
containing phospholipids were analyzed by 
LC/MS as described below. 
 
Macrophage stimulation - Cells were placed in 
serum-free medium for 30 min before addition 
of zymosan (1 mg/ml) for the time indicated. 
Subsequently, supernatants were used for 
PGE2 and LTB4 determination, and the cell 
monolayers were scraped twice with ice-cold 
water. Cell phospholipids were extracted and 
prepared for AA content analysis by GC/MS as 
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described below. Zymosan was prepared as 
described elsewhere [27]. Briefly, zymosan 
particles were suspended in PBS, boiled for 60 
min, and washed three times. The final pellet 
was resuspended in PBS at 20 mg/ml and 
stored frozen. Zymosan aliquots were diluted 
in serum-free medium and sonicated before 
being added to the cells. No endogenous 
phospholipase A2 activity was detected in the 
zymosan batches used in this study, as 
assessed by in vitro activity assay utilizing 
substrates in the form of vesicles, mixed 
micelles or natural membranes in the presence 
or absence of calcium [28-31].  
 
Determination of PGE2 and LTB4 production - 
Supernatants from zymosan-stimulated cells 
were collected and assayed for PGE2 or LTB4 
using ELISA kits from Sapphire Bioscience 
(Waterloo, New South Wales, Australia), 
following the manufacturers' instructions.  
 
Assay for CoA-independent transacylase 
activity - CoA-independent transacylase 
activity was measured following the procedure 
originally described by Venable et al. [32] with 
slight modification. Briefly, the assay mixture 
was composed of 120 mM NaCl, 2 mM 
EGTA, 100 mM Tris-HCl (pH 7.5), cell 
homogenate (up to 100 µg of protein) and 5 
µM 1-O-[3H]hexadecyl-2-lyso-sn-glycero-3-
phosphocholine (lyso platelet-activating factor, 
lysoPAF) as a substrate, in a final volume of 
0.2 ml. The assay mix also contained 10 µM 
thimerosal to inhibit endogenous CoA-
dependent acyltransferase activity [33]. 
Preliminary experiments demonstrated that at 
the indicated concentration, thimerosal 
quantitatively inhibited CoA-dependent 
acyltransferase activities in macrophage 
homogenates, as judged by in vitro assay [34]. 
After incubation at 37°C for 5 min, the 
reaction was stopped by the addition of 0.75 
ml of chloroform/methanol (1:2). Chloroform 
(0.25 ml) and water (0.25 ml) were added and 
the mixture was vortexed vigorously before 
centrifugation at 1000 x g for 5 min. The 
organic phase was evaporated and 
chromatographed on Silica gel G plates with 
chloroform/methanol/ammonia 28% (65:25:5 
by vol) as the developing solvent. PC and 
lysoPAF were cut out of the plate and assayed 
for radioactivity by liquid scintillation 
counting. 
 
Gas chromatography/mass spectrometry 
analysis (GC/MS) of fatty acid methyl esters – 
The phospholipid fraction, isolated by thin-
layer chromatography with hexane/ether/acetic 
acid (70:30:1, v/v/v) as a mobile phase, was 
transmethylated with 500 µl of 0.5 M KOH in 
MeOH for 30 min at 37°C. One volume of 0.5 
M HCl was added to neutralize and fatty acid 
methyl esters were extracted twice with 2 
volumes of n-hexane. Analysis of fatty acid 
methyl esters was carried out in an Agilent 
6890N gas chromatograph coupled to an 
Agilent 5975 mass-selective detector (MSD) 
operated in electron impact mode (EI, 70 eV), 
equipped with an Agilent DB23 column (60 m 
x 0.25 mm I.D. x 0.15 µm film thickness), 
under the conditions described previously [35].  
 
HPLC-MS coupling- For HPLC separation of 
lipids, a Hitachi LaChrom Elite® L-2130 
binary pump was used, together with a Hitachi 
Autosampler L-2200 (Merck). The HPLC 
system was coupled on-line to a Bruker 
esquire6000 ion-trap mass spectrometer 
(Bruker Daltonics, Bremen, Germany). The 
effluent was split, and 0.2 ml/min was 
introduced in the ESI interface of the mass 
spectrometer. The nebulizer was set to 30 psi, 
the dry gas to 8 l/min and the dry temperature 
to 365 ºC. 
 
Analysis of PI, PE  and PC species- Total lipid 
content corresponding to 2·106 cells was 
extracted according to Bligh and Dyer [25]. 
After evaporation of the organic solvent under 
vacuum, the lipids were redissolved in 
methanol/water (9:1), and stored under 
nitrogen at -80 ºC until analysis. The column 
was a Supelcosil LC-18 (5 µm particle size, 
250 x 2.1 mm) (Sigma-Aldrich) protected with 
a Supelguard LC-18 20·2.1 mm guard 
Cartridge (Sigma-Aldrich). Mobile phase was 
a gradient of solvent A (meth-anol/water/n-
hexane⁄30% ammonium hydroxide, 
87.5:10.5:1.5:0.5, v/v), and solvent B 
(methanol/n-hexane⁄30% ammonium 
hydroxide, 87.5:12:0.5, v/v). The gradient was 
started at 100% solvent A, and was decreased 
linearly to 65% solvent A in 20 min, to 10% in 
5 min, and to 0% in another 5 min. Flow rate 
was 0.5 ml/min, and 80 µl of the lipid extract 
was injected. PI and PE species were detected 
in negative ion mode with the capillary current 
set at +3500 V over the initial 22 min as [M-
H]-. PC species were detected over the elution 
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interval from 22 to 35 min in positive ion 
mode as [M + H]+ ion with the capillary 
current set at -4000 V.  
 AA-containing PI and PE species were 
identified by multiple reaction monitoring 
MS/MS experiments on chromatographic 
effluent by comparison with previously 
published databases [36-38]. Cut-off parameter 
was set at m/z 150 and fragmentation 
amplitude at 1 (arbitrary units). Due to the 
lability of vinyl ether linkages in acid media, 
plasmanyl (1-alkyl) and plasmenyl (1-alk’1’-
enyl) glycerophospholipids were distinguished 
by acidifying the samples before lipid 
extraction [39]. For the identification of acyl 
chains of AA-containing PC species, 
ionization was carried out in negative mode 
with post-column addition of acetic acid at a 
flow rate of 100 µl/h as [M+CH3CO2]- adducts, 
and acyl chains were identified by MS3 
experiments [40, 41].  
 
Measurement of lipid phosphorus - Lipid 
phosphorus was measured as described 
previously [42], with slight modification of the 
procedure. After digestion of lipids with 0.9 ml 
of 70% perchloric acid at 200°C for 30 min, 
the samples were cooled in a water stream, and 
4 ml of distilled water was added, followed by 
0.5 ml of 2.5% ammonium molybdate and 0.5 
ml of 10% ascorbic acid. This mixture was 
thoroughly mixed and incubated at 100°C for 8 
min and absorbance read at 820 nm. 
 
Statistical analysis – All experiments were 
carried out at least three times with incubations 
in duplicate or triplicate. Statistical analysis 
was carried out by the Student’s t test, with p 
values < 0.05 taken as statistically significant.  
 
 
RESULTS 
 
Role of caveolin-1 on the incorporation of AA 
and other fatty acids in mouse peritoneal 
macrophages – Owing to its fatty acid-binding 
properties, caveolin-1 may be involved in 
cellular fatty acid uptake [23]. To assess a 
possible role for caveolin-1 in AA 
incorporation into the various lipid classes of 
mouse peritoneal macrophages, cells from the 
caveolin-1 null mouse strain described by 
Lisanti and co-workers [20] and from their 
littermate wild type controls were exposed to 
various concentrations of [3H]AA,  and the 
incorporation into phospholipid versus TAG 
was measured. The results are shown in Table 
I (top panel). In agreement with previous 
observations [43], at low levels of fatty acid 
there was negligible incorporation of AA into 
TAG and most of the fatty acid was 
incorporated in phospholipids; however, 
increasing the concentration of the fatty acid 
resulted in a significant incorporation into 
TAG as well. This behavior was found in both 
control and caveolin-1 deficient cells and is 
fully consistent with previous results indicating 
the preferential incorporation of AA into 
phospholipids in macrophages via a high 
affinity pathway (the Lands cycle of 
deacylation/reacylation), followed by a second 
pathway of lower affinity (the de novo route) 
that primarily operates when the former has 
been saturated, and leads to AA incorporation 
into TAG [2, 3]. Strikingly however, 
regardless of the concentration of AA utilized, 
the caveolin-1 deficient cells always 
incorporated significantly higher quantities of 
fatty acid than did the control cells in both 
phospholipid and TAG. Total amount of 
phospholipid and TAG did not significantly 
differ in control versus caveolin-1-deficient 
cells (phospholipid: 10.02 ± 0.56 nmol/106 
cells in control cells, and 9.96 ± 0.46 nmol/106 
cells caveolin-1-deficient cells; TAG: 64.56 ± 
0.99 nmol/106 cells in control cells, and 67.46 
± 1.02 nmol/106 cells in caveolin-1-deficient 
cells; means ± SEM, n=3). After addition of 10 
µM AA, the amount of phospholipid or TAG 
did not significantly change in either control or 
caveolin-1-deficient cells. 
 To confirm that the increase in the 
initial incorporation of AA in macrophage 
lipids is of biological significance and not the 
result of a peculiarity of the mouse strain 
utilized, we repeated the experiments 
described above with cells from another mouse 
strain lacking caveolin-1 by genetic ablation, 
i.e. that described by Kurzchalia and associates 
[19]. The results, shown in Table I (bottom 
panel), were almost identical to those observed 
with the previous strain, i.e. a highly 
significant increase in the incorporation of AA 
into both phospholipid and TAG in caveolin-1-
deficient cells versus control cells. In addition, 
the mass of fatty acid incorporated  in both 
strains was very similar, albeit a bit lower in 
the cells from mice described by Lisanti and 
co-workers [20]. Given these similarities, all 
successive experiments were carried out with 
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the strain produced by Lisanti and co-workers 
[20], as this one was more accesible to us. 
 Fig. 1 shows that cells deficient in 
caveolin-1 not only displayed an increased 
incorporation of AA when exposed to this fatty 
acid, but also when exposed to other fatty 
acids, whether saturated (palmitic acid, 16:0), 
mono- (oleic acid, 18:1n-9) or poly-
unsaturated (docosahexaenoic acid, 22:6n-3). 
Collectively, these results indicate that in 
peritoneal macrophages lacking caveolin-1, the 
initial incorporation of fatty acids into cellular 
lipids is more active than in cells expressing 
normal caveolin-1 levels. 
 
Metabolipidomic analysis of AA incorporation 
into cell phospholipids – To study the 
phospholipids that initially incorporate AA 
immediately after addition of the fatty acid to 
the cells, a LC/MS/MS metabolipidomic 
approach was followed, where the cells were 
incubated with deuterated AA. Newly 
synthesized [2H]AA-containing phospholipids 
were unequivocally identified by their bell-
shaped isotopic distribution with a maximum 
at +8 m⁄z apart from their native counterparts, 
due to the [2H]AA isotopomers [44]. We have 
recently employed this technique to identify 
novel AA-containing phospholipids in human 
monocytes [40]. Fig. 2 shows the phospholipid 
species that incorporated [2H]AA after a 30-
min incubation of the cells with the fatty acid. 
Four [2H]AA-containing PC species were 
identified. The most abundant species, both in 
caveolin-1-deficient and control cells was 
PC(16:0/[2H]AA), albeit it was significantly 
more abundant in the caveolin-1-deficient 
cells. Two other major PC species 
incorporating [2H]AA were PC(18:0/[2H]AA) 
and PC(18:1/[2H]AA), and these were found at 
similar levels in caveolin-1-deficient and 
control cells. Finally, the ether species PC(O-
18:1/[2H]AA) was detected in caveolin-1-
deficient cells but not in control cells (Fig. 2). 
As expected [45], no [2H]AA incorporation 
into PE species was detected in control cells 
expressing normal caveolin-1 levels (Fig. 2). 
Importantly however, a very significant 
incorporation of the fatty acid was found in the 
plasmalogen species PE(P-16:0/[2H]AA) in 
caveolin-1-deficient cells (Fig. 2). Regarding 
PI species, 4 of these were detected in both 
caveolin-1-deficient and control cells, namely 
PI(18:0/[2H]AA), PI(18:1/[2H]AA), 
PI(16:0/[2H]AA) and PI([2H]AA/[2H]AA), and 
all of them were increased in the caveolin-1-
deficient cells (Fig. 2).  
 Total amount of PC, PE and PI in 
control macrophages was 4.6 ± 0.2, 2.4 ± 0.1, 
and 0.8 ± 0.1 nmol/106 cells respectively 
(means ± SEM, n=3). These amounts did not 
significantly differ from those found in 
caveolin-1-deficient cells. Based on these 
amounts, we calculated that at 30 min, control 
cells incorporated approx. 15 pmol of [2H]AA 
per nmol of PC, and 22 pmol of [2H]AA per 
nmol of PI. In contrast, caveolin-1-deficient 
cells incorporated 20 pmol of [2H]AA per 
nmol of PC, 2 pmol of [2H]AA per nmol of 
PE, and 45 pmol of [2H]AA per nmol of PI. 
The ratio of AA incorporation in PC vs PE vs 
PI at 30 min was 79:0:21 in control cells, and 
71:4:25 in caveolin-1-deficient cells. 
 
Lipidomic profile of endogenous phospholipids 
in caveolin-1-deficient versus control cells – 
The results of Fig. 2 show that the profile of 
AA-containing phospholipids that are formed 
immediately after addition of the fatty acid to 
the cells is qualitatively and quantitatively 
different in caveolin-1-deficient versus control 
cells. It was therefore important to investigate 
whether these initial alterations persist over 
time. To this end, as a measure of the 
equilibrium, steady-state conditions, we 
conducted a full lipidomic analysis of 
endogenous phospholipid species in caveolin-
1-deficient versus control cells. Fig. 3 
compares the fatty acid content of 
phospholipids of control versus caveolin-1 null 
cells, as measured by gas 
chromatography/mass spectrometry. No 
significant changes were found in any of the 
fatty acids measured, including AA. The latter 
comprised 15-20% of total fatty acids present 
in the phospholipids of these cells, which is in 
accordance with previous estimates [46]. 
Strikingly however, when endogenous AA-
containing phospholipids were profiled by 
LC/MS/MS (Fig. 4), remarkable alterations 
were observed. Thus, although the lack of 
caveolin-1 did not modify the steady-state 
level of AA esterified in phospholipids, the 
distribution of this fatty acid between 
phospholipids was profoundly altered, 
resulting in significantly decreased levels of 
AA in PC which were counteracted by 
increases in PE and PI. The ratio of AA 
present in the different classes of 
phospholipids, PC vs PE vs PI, was changed 
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from  27:54:19  in control cells  to 14:59:27 in 
caveolin-1-deficient cells. Note that the 
relative amounts of AA in each phospholipid 
class in the equilibrium is substantially 
different from that observed in the 
metabolipidomic experiments at 30 min, both 
for control and caveolin-1-deficient cells (see 
preceding paragraph).   
 The distribution of AA among 
phospholipid classes ultimately depends on 
transacylation reactions that are catalyzed by 
CoA-dependent transacylase (CoA-IT). This 
enzyme continuously transfers AA moieties 
from PC species to PE species, and is therefore 
responsible for maintaining the high level of 
AA in PE in phagocytes, despite that PC is the 
major acceptor for the initial incorporation of 
the fatty acid (Fig. 2, and ref. 2). The 
alterations in the distribution of AA among 
phospholipid classes in control vs caveolin-1-
deficient cells, in particular the AA decrease in 
PC and increase in PE, is highly suggestive of 
alterations at the level of CoA-IT. 
Unfortunately, the nucleotide sequence of the 
gene coding for CoA-IT remains unknown, 
which prevents us from using genetic 
approaches to characterize the effect of 
caveolin-1 depletion on CoA-IT. Thus in the 
current experiments, CoA-IT was studied by 
following its enzymatic activity by in vitro 
assay. The results are shown in Fig. 5 and 
indicate that the measurable CoA-IT activity of 
homogenates from caveolin-1 null cells was 
significantly higher than that of homogenates 
of control cells displaying normal caveolin-1 
levels. 
 LC/MS/MS lipidomic analyses of 
major phospholipid species not containing AA 
were also conducted, and the results are shown 
in Fig. 6. Since in many cases fragmentation of 
the m/z peaks detected in MS analyses yielded 
fragments corresponding to various species, it 
was not always possible to unequivocally 
assign structures to these m/z peaks. Thus, the 
data are given in abbreviated form, indicating 
phospholipid class, number of carbon atoms 
and double bonds of the two lateral chains. 
Regarding PC species, the most striking 
difference was that of PC(32:0), which was 
strongly reduced in the caveolin-1-deficient 
cells. This species could be identified as 
PC(16:0/16:0) in fragmentation experiments. 
Regarding PE, various species were found to 
be significantly increased in caveolin-1-
deficient cells. The most prominent were PE 
(34:1), PE(36:2), PE(40:6), and PE(40:4). The 
first two represent a mix of various species, but 
the latter two could be identified as 
PE(18:0/22:4) and PE(18:0/22:6) in 
fragmentation experiments. 22:4 is adrenic 
acid, the superior homologue of AA, and thus 
it is notable that the two closely related species 
PE(18:0/22:4) and PE(18:0/20:4) were found 
to be increased in caveolin-1-deficient cells 
(cf. Figs. 3 and Fig. 6). Regarding PI, only 3 
species not containing AA were detected, one 
of which, PI(40:4), was found in caveolin-1-
deficient but not in control cells. This species 
was unequivocally identified as PI(18:0/22:4) 
and, similar to the PE species described above, 
note that the species PI(18:0/20:4) was also 
increased in caveolin-1-deficient cells. 
 AA mobilization and eicosanoid 
production in caveolin-1-deficient cells – Free 
AA mobilization during cell activation 
represents a balance between what is released 
from phospholipids by phospholipase A2s 
minus what is reincorporated back into 
phospholipids by acyltransferases and 
transacylases. Given the profound alterations 
detected in phospholipid fatty acid 
incorporation and remodeling in caveolin-1-
deficient macrophages, it was of interest to 
explore the mobilization of free AA and 
attendant eicosanoid production when these 
cells were activated by an 
immunoinflammatory stimulus. The cells were 
challenged with yeast-derived zymosan, a 
potent inducer of the AA mobilization 
response in peritoneal macrophages [47-49], 
and total AA mobilized from cellular 
phospholipids after the challenge was analyzed 
by GC/MS. Caveolin-1-deficient cells retained 
more AA in phospholipids than did control 
cells after the challenge (Fig. 7A), indicating a 
considerably lower AA mobilization to the 
medium (17.9 ± 0.6 % decrease; mean ± SEM, 
n=6). This finding is consistent with the 
previous observations that caveolin-1-deficient 
cells incorporate AA into phospholipids at a 
higher rate than control cells (Table I), hence 
higher amounts of AA are retained by the cells. 
Analyses by GC/MS of the phospholipid 
classes that generated the AA which was lost 
after stimulation of control and caveolin-1-
deficient cells, indicated that both PC and PI 
behaved as sources of released AA. On the 
contrary, the levels of AA-containing PE 
remained fairly constant after the zymosan 
challenge. This situation is remarkably similar 
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to that previously reported for zymosan-
stimulated murine macrophages and 
RAW264.1 macrophage-like cells [50] and 
zymosan-stimulated human monocytes [41]. It 
is remarkable that in terms of total mass, the 
amount of AA lost from PI in control and 
caveolin-1-deficient cells was very similar  
(0.67 ± 0.09 and 0.73 ± 0.11 nmol/106 cells for 
control and caveolin-1-deficient cells, 
respectively; means ± SEM, n=3). The amount 
of AA lost from PC was 1.24 ± 0.18 and 0.54 
± 0.07 nmol/106 cells for control and caveolin-
1-deficient cells, respectively; means ± SEM, 
n=3). 
 Consistent with reduced mobilization 
of free AA, caveolin-1-deficient cells also 
produced reduced amounts of PGE2 and LTB4 
after zymosan stimulation (Fig. 7B and C). 
 
 
DISCUSSION 
 
Caveolin-1 is expressed in all cells and tissues, 
albeit it is especially abundant in adipocytes 
and endothelial cells [14]. Caveolin-1 and 
caveolae are also present in all innate immune 
cells, although their expression level and 
distribution appears to strikingly depend on the 
activation and/or maturation state of the cell 
[16]. Caveolin-1 has been unambiguously 
identified in murine macrophages and mast 
cells [18, 51-53] as well as human dendritic 
cells and neutrophils [54, 55]. 
 It has been shown that both caveolin-1 
isoforms, α and β, can bind free fatty acids to 
facilitate their uptake by adipocytes via the 
caveolae system with the participation of fatty 
acid transporters like FAT/CD36 [23, 56, 57]. 
Given these previous data, we were interested 
in assessing the role of caveolin-1 in the 
uptake and esterification of AA into the 
phospholipids of macrophages. Although 
macrophages are not particulary enriched in 
caveolin-1 or caveolae [14], they do exhibit a 
high capacity to incorporate AA into 
membrane phospholipids [2, 3]. Such a process 
is of great relevance from a pathophysiological 
point of view, since one of the limiting factors 
for the synthesis of bioactive eicosanoids 
during inflammation is the availability of free 
AA.  
Studies on the initial incorporation of 
AA in macrophage lipids from caveolin null 
mice versus their wild type littermates indicate 
that most of the fatty acid is incorporated in 
phospholipids and only a minor fraction is 
incorporated in TAG, and this occurs at all 
concentrations tested. Strikingly however, 
macrophages from the caveolin-1 null mice 
consistently incorporate more AA and other 
fatty acids, both saturated and unsaturated, 
than macrophages from wild type animals. Of 
note, identical results were obtained when the 
experiments were repeated utilizing a second, 
different caveolin-1 null mice strain, thus 
demonstrating that the effect is 
pathophysiologically relevant and not the 
result of a strain-specific peculiarity. 
 Caveolin-1 null mice have been found 
to exhibit severely elevated TAG and free fatty 
acid levels, especially in the post-prandial state 
[21, 58, 59]. These metabolic defects observed 
in caveolin-1 null mice have underscored the 
role of this protein for proper lipid transport in 
the adipocyte [13, 58]. On the other hand, 
studies with mouse embrionary fibroblasts 
from caveolin-1 null mice have suggested that 
the lack of caveolae and caveolin-1 results in 
diminished incorporation of oleic acid into 
cellular lipids, a finding that was related to the 
loss of expression of the fatty acid transporter 
FAT/CD36 [57, 60]. That in peritoneal 
macrophages from caveolin-1 null mice the 
initial incorporation of exogenous AA and 
other fatty acids is increased is therefore 
striking. We speculate that the relatively lower 
content of caveolin-1 and caveolae in 
macrophages compared with that of adipocytes 
and fibroblasts may likely explain these 
differences. Macrophages may exhibit 
regulatory features for the initial incorporation 
of potentially pro-inflammatory fatty acids 
such as AA, which are not present or are not 
operative in cells not directly implicated in 
innate immunity and inflammation [2, 3]. In 
this regard, it is worth mentioning the work by 
Wu et al. [61] demonstrating that in mice 
lacking the fatty acid transporter FATP1, fatty 
acid incorporation into adipose tissue and 
muscle lipids is impaired, whereas in liver and 
heart the opposite occurs. Thus, clear 
mechanistic differences between tissues with 
regard to fatty acid transport appear to actually 
exist, and these may account for the 
differences observed regarding the effect of 
caveolin-1 on fatty acid incorporation in 
different cell types. 
 Metabolipidomic analyses of the initial 
phospholipid acceptors to which AA 
incorporates revealed at least three striking 
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differences between macrophages from 
caveolin-1 null mice versus cells from control 
littermates that can be summarized as follows: 
(i) an increase in AA incorporation into some 
but not all PC species, (ii) the appearance of an 
AA-containing PE species in caveolin-1-
deficient cells that is not present in control 
cells, namely PE(P-16:0/20:4), and (iii) a 
general increase in the incorporation of AA 
into PI species, particularly PI(18:0/20:4). It is 
well established that accumulation of AA into 
PE species is a delayed process that takes 
hours to develop and takes place mainly at the 
expense of the AA initially incorporated into 
PC species via CoA-independent 
transacylation reactions [2]. Thus, the 
appearance of a PE species in the cells from 
caveolin-1 null mice as early as 30 min after 
addition of the fatty acid, is strongly indicative 
that an increased remodeling of AA-containing 
phospholipids via CoA-independent 
transacylase (CoA-IT) occurs in the caveolin-
1-deficient cells.  
With the recent cloning of mammalian 
Mg2+-dependent phosphatidate phosphatases 
(lipins) [62] and platelet-activating factor 
acetyl transferase [63], CoA-IT stands as the 
only lipid signaling and remodeling enzyme 
whose sequence remains unknown. Thus, 
currently the only manner to study the cell 
regulation of CoA-IT is by measuring its 
enzyme activity [35]. By doing this, we 
demonstrate that CoA-IT activity levels are 
markedly elevated in the absence of caveolin-
1. Thus these results identify a novel molecular 
alteration in caveolin-1-deficient cells, and 
suggest interesting implications as to the 
pathophysiological relevance of the finding. 
For example, it is well established that rapidly-
dividing cells such as tumor cells display 
higher CoA-IT-dependent phospholipid AA 
remodeling rates that non-tumor cells, the 
inhibition of which results in apoptotic cell 
death [64-67]. According to these data, it could 
be anticipated that cells from caveolin-1 null 
mice would be more susceptible to apoptosis 
than cells from wild type controls, and 
evidence in this regard has been put forth very 
recently [68].  
 Despite the increased rate of AA 
incorporation in caveolin-1-deficient versus 
wild type cells, the total mass of AA and other 
major fatty acids under equilibrium conditions 
(i.e. the endogenous fatty acid levels) did not 
significantly change. This is consistent with 
the notion that the initial rate of incorporation 
of a given fatty acid in cellular lipids does not 
determine the actual content of such fatty acid 
under steady-state conditions. Importantly 
however, the distribution of AA among 
phospholipids in the equilibrium still exhibited 
very marked changes, some of which 
(increases in PE and PI), but not all (decreases 
in PC), had already been detected in the 
metabolipidomic experiments measuring initial 
rates of incorporation. This altered distribution 
of AA among phospholipids in caveolin-1 null 
cells under equilibrium conditions is again 
fully consistent with the increased CoA-IT 
activity that these cells exhibit. Moreover, 
accelerated remodeling due to increased CoA-
IT activity may also help to explain the 
increased initial rate of incorporation of AA 
and other fatty acids into phospholipids, since 
the transfer of AA of PC to PE, and perhaps 
PI, will increase the availability of lysoPC 
acceptors for the acylation of new molecules of 
fatty acid [2]. That PI species, not only PE, 
also contribute to counteract the AA losses in 
PC seen in caveolin-1-deficient cells suggests 
that either lysoPI could serve as an acceptor 
for the CoA-IT-mediated reaction, which 
would be remarkable, or that the channeling of 
AA from PC to PI is the consequence of a 
second, independent molecular alteration of 
phospholipid AA remodeling. Studies are 
currently underway in our laboratory to 
explore these possibilities. 
 Another striking finding of this work 
is that the altered phospholipid composition of 
caveolin-1-deficient versus wild type cells is 
not limited to AA-containing phospholipids 
but to other species as well. In this regard, a 
major difference is the very reduced content of 
PC(16:0/16:0) in cells from caveolin-1-
deficient cells. The significance of such a 
dramatic reduction in peritoneal macrophages 
is unclear at present, but PC(16:0/16:0) is a 
major constituent of the pulmonary surfactant, 
and it is known that caveolin-1 null mice suffer 
from respiratory problems [19]. Thus it could 
be interesting to assess the levels of this 
phospholipid species and mechanisms of 
synthesis in cells from the lungs of caveolin-1 
null mice, to assess whether a relation exists.  
 Given that the amount of AA 
mobilized from cells for eicosanoid synthesis 
during an immunoinflammatory challenge 
depends on the relative activity of the two 
competing reactions of deacylation 
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(phospholipase A2) and reacylation (CoA-
dependent acyltransferase and CoA-IT) [3], a 
likely consequence of the elevated 
phospholipid AA incorporation and 
remodeling that caveolin-1-deficient cells 
display would be a reduced AA mobilization 
and eicosanoid generation responses under 
appropriate stimulation. We provide 
unambiguous evidence that this is exactly what 
happens when the cultured macrophages were 
exposed to the innate immunity stimulant 
zymosan. Analyses of the sources of the AA 
released upon zymosan challenge indicate that 
both in control and caveolin-1-deficient cells, 
PC and PI, but not PE, contribute to the 
response. Interestingly, stimulated caveolin-1-
deficient cells appear to mobilize similar 
amounts of AA from PI but not from PC than 
control cells, which may reflect the increased 
rate of incorporation of AA into PC and further 
phospholipid remodeling that these cells 
exhibit. On the other hand, based on previous 
work by our and other groups [2, 9-11, 40, 50, 
69-71] it seems possible that PE molecules 
also serve as immediate substrates for 
zymosan-induced AA mobilization but are 
rapidly reacylated using AA from other 
sources, i.e. PC, via CoA-IT. The stimulated 
entry of AA into PE via CoA-independent 
transacylation reactions has been demonstrated 
to occur in human neutrophils [9], human 
monocytes [41] and murine mast cells [70]. 
 
 
ACKNOWLEDGMENTS 
 
We thank Montse Duque and Yolanda Sáez for 
expert technical help. CIBERDEM is an 
initiative of Instituto de Salud Carlos III.  
 
 
 
REFERENCES 
 
  1. Funk, C.D. (2001) Science 294: 1871-1875.  
  2. Chilton, F. H., Fonteh, A. N., Surette, M. E., Triggiani, M., and Winkler, J. D. (1996) Biochim. 
Biophys. Acta. 1299: 1-15.  
  3. Pérez-Chacón, G., Astudillo, A. M., Balgoma, D., Balboa, M. A., and Balsinde, J. (2009) Biochim. 
Biophys. Acta 1791: 1103-1113.  
  4. Balsinde, J., Winstead, M. V., and Dennis, E. A. (2002) FEBS Lett. 531: 2-6.  
  5. Leslie, C. C. (2004) Biochem. Cell Biol. 82: 1–17.  
  6. Balsinde, J., and Balboa, M. A. (2005) Cell. Signal. 17, 1052-1062. 
  7. Balboa, M. A., and Balsinde, J. (2006) Biochim. Biophys. Acta 1761: 385-391.  
  8. Balsinde, J., Pérez, R., and Balboa, M. A. (2006) Biochim. Biophys. Acta 1761: 1344-1350.  
  9. Nieto, M. L., Venable, M. E., Bauldry, S. A., Greene, D. G., Kennedy, M., Bass, D. A., and 
Wykle, R. L. (1991) J. Biol. Chem. 266: 18699-18706.  
10. Balsinde, J., Barbour, S. E., Bianco, I. D., and Dennis, E. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 
91: 11060-11064.  
11. Boilard, E., and Surette, M. E. (2001) J. Biol. Chem. 276: 17568-17575.  
12. Balsinde, J. (2002) Biochem. J. 364: 695-702.  
13. Cohen, A. W., Hnasko, R., Schubert, W., and Lisanti, M. P. (2004) Physiol. Rev. 84: 1341-1379.  
14. Williams, T. M., and Lisanti, M. P. (2004) Genome Biol. 5: 214.  
15. Parton, R. G., and Simons, K. (2007) Nat. Rev. Mol. Cell Biol. 8: 185-194.  
16. Harris, J., Werling ,D., Hope, J. C., Taylor, G., and Howard, C. J. (2002) Trends Immunol. 23: 
158-164.  
17. Gargalovic, P., and Dory, L. (2003) J. Lipid Res. 44: 11-21.  
18. Shin, J. S., Gao, Z., and Abraham, S. N. (2000) Science 289: 785-788. 
19. Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., Lindschau, C., 
Mende, F., Luft, F. C., Schedl, A., Haller, H., and Kurzchalia, T. V. (2001) Science 293: 2449-
2452.  
20. Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., Macaluso, F., 
Russell, R. G., Li, M., Pestell, R. G., Di Vizio, D., Hou, H., Kneitz, B., Lagaud, G., Christ, G. 
J., Edelmann, W., and Lisanti, M. P. (2001) J. Biol. Chem. 276: 38121-38138.  
21. Razani, B., Combs, T. P., Wang, X. B., Frank, P. G., Park, D. S., Russell, R. G., Li, M., Tang, B., 
Jelicks, L. A., Scherer. P. E., and Lisanti, M. P. (2002) J. Biol. Chem. 277: 8635-8647.  
22. Heimerl, S., Liebisch, G., Le Lay, S., Bottcher, A., Wiesner, P., Lindtner, S., Kurzchalia, T. V., 
Simons, K., and Schmitz, G. (2008) Biochem. Biophys. Res. Commun. 367: 826-833.  
23. Trigatti, B. L., Anderson, R. G., and Gerber, G. E. (1999) Biochem. Biophys. Res. Commun. 255: 
34-39. 
24. Diez, E., Balsinde, J., Aracil, M., and Schüller, A. (1987) Biochim. Biophys. Acta 921: 82-89.  
25. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37: 911-917.  
26. Pérez-Chacón, G., Astudillo, A. M., Ruipérez, V., Balboa, M. A., Balsinde, J. (2010) J. Immunol. 
184: 1071-1078.  
27. Balsinde, J., Balboa, M. A., and Dennis, E. A. (2000) J. Biol. Chem. 275: 22544-22549.  
28. Balsinde, J., Balboa, M. A., Insel, P. A., and Dennis, E. A. (1997) Biochem. J. 321: 805-809.  
29. Balboa, M. A., Sáez, Y., and Balsinde, J. (2003) J. Immunol. 170: 5276-5280.  
30. Pérez, R., Balboa, M. A., and Balsinde, J. (2006) J. Immunol. 176: 2555–2561.  
31. Balboa, M. A., Pérez, R., and Balsinde, J. (2008) FEBS J. 275: 1915-1924. 
32. Venable, M. E., Nieto, M. L., Schmitt, J. D., and Wykle, R. L. (1991) J. Biol. Chem. 266: 18691-
18698.  
33. Kaever, V., Goppelt-Struebe, M., and Resch, K. (1988) Prostaglandins 35: 885-902. 
34. Balsinde, J., Bianco, I. D., Ackermann, E. J., Conde-Frieboes, K., and Dennis, E. A. (1995) Proc. 
Natl. Acad. Sci. U.S.A. 92: 8527-8531.  
35. Astudillo, A. M., Pérez-Chacón, G., Balgoma, D., Gil-de-Gómez, L., Ruipérez, V., Guijas, C., 
Balboa, M. A.,  and Balsinde, J. (2011) Biochim. Biophys. Acta 1811: 97–103.  
36. Brügger, B., Erben, G., Sandhoff, R., Wieland, F. T., and Lehmann, W. D. (1997) Proc. Natl. 
Acad. Sci. U. S. A.  94: 2339–2344. 
37. Murphy, R. C. (2002) Mass Spectrometry of Phospholipids: Tables of Molecular and Product Ions. 
Illuminati Press, Denver, CO. 
38. Pulfer, M., and Murphy, R. C. (2003) Mass Spectrom. Rev. 22: 332–364. 
39. Kayganich, K. A., and Murphy, R. C. (1992) Anal. Chem. 64: 2965–2971. 
40. Balgoma, D., Montero, O., Balboa, M. A., and Balsinde, J. (2008) FEBS J. 275: 6180-6191.  
41. Balgoma, D., Astudillo, A. M., Pérez-Chacón, G., Montero, O., Balboa, M. A., and Balsinde, J. 
(2010) J. Immunol. 184: 3857-3865.  
42. Rouser, G., Fleischer, S., and Yamamoto, A. (1970) Lipids 8, 494-496. 
43. Balsinde, J., and Dennis, E. A. (1996) Eur. J. Biochem. 235: 480-485.  
44. Balgoma, D., Montero, O., Balboa, M. A., and Balsinde, J. (2010) Biochimie 92: 645-650.  
45. Balsinde, J., Fernández, B., and Solís-Herruzo, J. A. (1994) Eur. J. Biochem. 221: 1013-1018.  
46. Scott, W. A., Pawlowski, N. A., Murray, H. W., Andreach, M., Zrike, J., and Cohn, Z. A. (1982) J. 
Exp. Med. 155: 1148-11460.  
47. Balsinde, J., Fernández, B., and Diez, E. (1990) J. Immunol. 144: 4298-4304.  
48. Balsinde, J., Fernández, B., Solís-Herruzo, J. A., and Diez, E. (1992) Biochim Biophys Acta 1136: 
75-82.  
49. Balsinde, J., Fernández, B., and Solís-Herruzo, J. A. (1994) Biochim. Biophys. Acta 1210:195-201. 
50. Rouzer, C. A., Ivanova, P. T., Byrne, M. O., Brown, H. A., and Marnett, L. J. (2007) Biochemistry 
46: 6026-6042. 
51. Kiss, A. L., and Kittel, A. (1995) Cell. Biol. Int. 19: 527-538.  
52. Kiss, A. L., and Geuze, H. J. (1997) Eur. J. Cell. Biol. 73: 19-27.  
53. Balboa, M. A., Shirai, Y., Gaietta, G., Ellisman, M. H., Balsinde, J., and Dennis, E. A. (2003) J. 
Biol. Chem. 278: 48059-48065.  
54. Yan, S. R., Fumagalli, L., and Berton, G. (1996) FEBS Lett. 380: 198-203.  
55. Werling, D., Hope, J. C., Chaplin, P., Collins, R. A., Taylor, G., and Howard, C. J. (1999) J. 
Leukoc. Biol. 66: 50-58.  
56. Pohl, J., Ring, A., Ehehalt, R., Schulze-Bergkamen, H., Schad, A., Verkade, P., and Stremmel, W. 
(2004) Biochemistry 43: 4179-4187.  
57. Ehehalt, R., Fullekrug, J., Pohl, J., Ring, A., Herrmann, T., and Stremmel, W. (2006) Mol. Cell. 
Biochem. 284: 135-140.  
58. Hnasko, R., and Lisanti, M. P. (2003) Mol. Interv. 3: 445-464. 
  10
59. Le Lay, S, and Kurzchalia, T. V. (2005) Biochim. Biophys. Acta. 1746: 322-333.  
60. Ring, A., Le Lay, S., Pohl, J., Verkade, P., and Stremmel, W. (2006) Biochim. Biophys. Acta 1761: 
416-423.  
61. Wu, Q., Ortegon, A. M., Tsang, B., Doege, H., Feingold, K. R., and Stahl, A (2006) Mol. Cell. 
Biol. 26: 3455-3467.  
62. Carman, G. M., and Han, G. S. (2009) J. Biol. Chem. 284: 2593–2597.  
63. Morimoto, R., Shindou, H., Oda, Y., and Shimizu, T. (2010) J. Biol. Chem. 285: 29857–29862. 
64. Surette, M. E.,  Fonteh, A. N., Bernatchez, C., and Chilton, F. H. (1999) Carcinogenesis 20: 757–
763.  
65. Trimboli, A. J., Waite, B. M., Atsumi, G., Fonteh, A. N., Namen, A. M., Clay, C. E., Kute, T. E., 
High, K. P., Willingham, M. C., and Chilton, F. H. (1999) Cancer Res. 59: 6171-6177.  
66. Pérez, R., Matabosch, X., Llebaria, A., Balboa, M. A., and Balsinde, J. (2006) J. Lipid Res. 47: 
484-491.  
67. Pérez, R., Melero, R., Balboa, M. A., and Balsinde, J. (2004) J. Biol. Chem. 279: 40385-40391. 
68. Bosch, M., Mari, M., Herms, A., Fernández, A., Fajardo, A., Kassan, A., Giralt, A., Colell, A., 
Balgoma, D., Barbero, E., González-Moreno, E., Matias, N., Tebar, F., Balsinde, J., Camps, 
M., Enrich, C., Gross, S. P., García-Ruiz, C., Pérez-Navarro, E., Fernández-Checa, J. C., and 
Pol, A. (2011) Curr. Biol. 21: 681-686.  
69. Balsinde, J., and Dennis, E. A. (1996) J. Biol. Chem. 271: 6758-6765. 
70. Fonteh, A. N., and Chilton, F. H. (1992) J. Immunol. 148: 1784-1791. 
71. Fonteh, A. N., and Chilton, F. H. (1993) J. Immunol. 150: 563-570. 
 
 
 
FOOTNOTES 
 
*This work was supported by the Spanish Ministry of Science and Innovation (Grants BFU2010-
18826 and SAF2010-18831). A.M.A. was supported by a predoctoral fellowship from the Regional 
Government of Castile and León.  
 
1The abbreviations used are: AA, arachidonic acid; CoA-IT, coenzyme A-independent transacylase; 
GC/MS, gas chromatography/mass spectrometry; LC/MS, liquid chromatography/mass spectrometry; 
PC, choline glycerophospholipids; PE, ethanolamine glycerophospholipids; PI, phosphatidylinositol;  
TAG, triacylglycerol. 
 
 
FIGURE LEGENDS 
 
Figure 1 – Incorporation of different fatty acids into cellular lipids of control and caveolin-deficient 
cells. The indicated fatty acids were given to the control (filled bars) or caveolin-1-deficient (open 
bars) cells at 10 µM for 30 min. Afterward, fatty acid incorporation into phospholipids (A) or TAG 
(B) was determined. Data are shown as means ± SEM of three independent determinations (*p < 
0.05). 
 
Figure 2 – Analysis of the phospholipid species to which exogenous [2H]AA initially incorporates. 
Cells from control (filled bars) or caveolin-1-deficient (open bars) mice were exposed to [2H]AA for 
30 min. The incorporation of [2H]AA into PC (red), PE (green) or PI (blue) species was determined by 
LC/MS/MS. Data represent the [2H]AA distribution after a 30-min period of exposure to the cells, and 
are shown as means ± SEM of five independent determinations (*p < 0.05). 
 
Figure 3 – Fatty acid content of phospholipids from control and caveolin-1-deficient cells. The 
phospholipid fatty acid profile in control (filled bars) or caveolin-deficient (open bars) was determined 
by GC/MS after converting the fatty acid glyceryl esters into fatty acid methyl esters. Data are 
expressed as means ± SEM of five independent determinations. 
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Figure 4 – AA-containing phospholipid species in control and caveolin-1-deficient cells. The profile 
of AA-containing PC (red), PE (green) and PI (blue) species in control (filled bars) or caveolin-1-
deficient (open bars) cells was determined by LC/MS/MS. Data represent the equilibrium distribution 
of AA and are shown as means ± SEM of five independent determinations (*p < 0.05). 
 
Figure 5 – CoA-IT activity is augmented in homogenates from caveolin-1-deficient cells. 
Homogenates were prepared from control cells and caveolin-1-deficient cells as indicated, and total 
CoA-IT activity was measured by in vitro assay. Data are given as means ± SEM of five independent 
determinations (*p < 0.05). 
 
Figure 6 – Phospholipid species not containing AA in control and caveolin-1-deficient cells.  The 
profile of PC (panel A), PE (Panel B) and PI (panel C) species in control (filled bars) or caveolin-1-
deficient (open bars) cells was determined by LC/MS/MS. Data are shown as means ± SEM of five 
independent determinations (*p < 0.05). 
 
Figure 7 – AA mobilization and eicosanoid production in control and caveolin-1-deficient mice.  
Peritoneal macrophages from control and caveolin-1-deficient mice were incubated in the absence 
(open bars) or presence of zymosan (filled bars) for 1 h. Afterward the supernatants were collected for 
PGE2 and LTB4 analyses by ELISA (panels B and C respectively) and phospholipid AA content in the 
cell monolayers was determined by GC/MS (panel A).  The data are shown as means ± SEM of six 
independent determinations (*p < 0.05). 
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TABLE I 
 
The initial incorporation of [3H]AA in phospholipids and TAG in macrophages from caveolin-1-
deficient and control cells. 
 
The cells were incubated with the indicated concentrations of [3H]AA (0.25 µCi/ml) for 30 min. After 
lipid extraction, the amount of radioactivity in phospholipids and TAG was measured.  Panel A shows 
the results utilizing cells from the mice described by Lisanti and co-workers (Razani et al., 2001). 
Panel B shows the results utilizing cells from the mice described by Kurzchalia and co-workers (Drab 
et al., 2001). Asterisks denote significant differences in caveolin-1-deficient versus control cells (p < 
0.05). The results are given as pmol/106 cells, and are means ± SEM of three independent experiments 
with duplicate incubations. 
 
A 
Phospholipids  TAG [3H]AA 
(µM) Control Cav-1-deficient Control Cav-1-deficient 
0.001 (11.4 ± 0.1)·10-3 (21.9 ± 0.4)·10-3* (0.8 ± 0.1)·10-3 (0.9 ± 0.1)·10-3 
0.10 1.1 ± 0.1 1.7 ± 0.1* 0.1 ± 0.1 0.1 ± 0.1 
1 9.1 ± 0.9 16.3 ± 1.5* 1.1 ± 0.1 1.5 ± 0.2 
10 57.8 ± 2.9 106.7 ± 2.6* 10.1 ± 1.3 17.0 ± 0.3* 
 
 
B 
Phospholipids TAG [3H]AA 
(µM) Control Cav-1-deficient Control Cav-1-deficient 
0.001 (16.2 ± 0.1)·10-3 (18.4 ± 1.9)·10-3 (1.3 ± 0.1)·10-3 (1.6 ± 0.1)·10-3* 
0.1 1.3 ± 0.1 2.6 ± 0.1* 0.1. ± 0.1 0.2 ± 0.1 
1 11.3 ± 0.1 14.2 ± 0.9 1.7. ± 0.2 2.6 ± 0.2* 
10 69.2 ± 0.8 100.4 ± 4.9* 23.5 ± 2.1 36.2 ± 1.9* 
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